Belantamab mafodotin (belamaf)‐containing regimens are effective treatment options for patients with relapsed and/or refractory multiple myeloma. Ocular events are a common adverse effect of belamaf treatment, which can be managed… Click to show full abstract
Belantamab mafodotin (belamaf)‐containing regimens are effective treatment options for patients with relapsed and/or refractory multiple myeloma. Ocular events are a common adverse effect of belamaf treatment, which can be managed by physicians, following appropriate training, to minimize their impact on the patient.
Keywords:
practical guidance;
ocular events;
guidance clinical;
belantamab mafodotin
Journal Title: American Journal of Hematology
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: American Journal of Hematology
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!